Delivered as a once-daily 30 mg/mL IV bolus injection over 15 seconds, Xifyrm can be used alone or alongside non-NSAID ...

Vertex and Eli Lilly are revolutionizing non-opioid pain management with NaV1.8 advancements. See why I'm bullish about LLY ...

Journavx received FDA approval, the agency announced on Thursday, Jan. 30. The drug developed by Boston-based Vertex Pharmaceuticals blocks sodium channels in the peripheral nervous system ...

Four months after Vertex Pharmaceuticals Inc.’s U.S. FDA nod for Journavx (suzetrigine) as the first drug targeting NaV1.8 for treating pain, Eli Lilly and Co. is joining the potential competition via ...

Look for Journavx to become a massive blockbuster drug for Vertex. It won U.S. Food and Drug Administration (FDA) approval earlier this year for treating acute pain. The big plus for Journavx is that ...

Vertex’ (Nasdaq: VRTX) Journavx (suzetrigine) was the first non-opioid pain drug green lighted by the Food and Drug Administration (FDA). All the news that moves the needle in pharma and biotech ...

So JOURNAVX is a NaV1.8 inhibitor ... We have initiated these conversations with the FDA, but we haven't concluded them. We're going to have our end of Phase 2 meeting this summer, and I expect ...

Detailed price information for Vertex Pharmaceutic (VRTX-Q) from The Globe and Mail including charting and trades.

Journavx, a sodium-channel inhibitor that blocks pain signals, is effective but non-addictive, and is the first new class of pain medication approved by the US Food and Drug Administration (FDA ...

The encouraging result comes just days after the US FDA approved Vertex Pharma's non-opioid painkiller Journavx (suzetrigine), an oral NaV1.8 inhibitor, as a treatment for acute pain, representing ...